{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+injection+of+saline+solution",
    "query": {
      "intervention": "Single injection of saline solution"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 598,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+injection+of+saline+solution&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T17:42:38.381Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01412008",
      "title": "Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stroke",
        "Muscle Spasticity"
      ],
      "interventions": [
        {
          "name": "Botox (botulinum toxin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Presbyterian Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 5,
      "start_date": "2010-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-10-01",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01412008"
    },
    {
      "nct_id": "NCT04646603",
      "title": "MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "ARDS, Human",
        "Stem Cells",
        "Regeneration"
      ],
      "interventions": [
        {
          "name": "MRG-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedRegen LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-12-01",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04646603"
    },
    {
      "nct_id": "NCT02357459",
      "title": "Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "FX006",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TCA IR 40",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 486,
      "start_date": "2015-01",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357459"
    },
    {
      "nct_id": "NCT05705024",
      "title": "Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Corneal Ulcer"
      ],
      "interventions": [
        {
          "name": "Mesenchymal Stromal Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2023-09-29",
      "completion_date": "2026-09-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05705024"
    },
    {
      "nct_id": "NCT03787290",
      "title": "Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Whole-Body Hyperthermia",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-12-01",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03787290"
    },
    {
      "nct_id": "NCT05118620",
      "title": "Pericapsular Nerve Group Block (PENG) for Hip Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hip Arthropathy",
        "Postoperative Pain, Acute",
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Active bupivacaine 0.375% PENG block",
          "type": "DRUG"
        },
        {
          "name": "Placebo normal saline PENG block",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-12-09",
      "completion_date": "2022-05-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-03",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05118620"
    },
    {
      "nct_id": "NCT02734862",
      "title": "CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Candidemia",
        "Mycoses",
        "Fungal Infection",
        "Fungemia",
        "Invasive Candidiasis"
      ],
      "interventions": [
        {
          "name": "CD101",
          "type": "DRUG"
        },
        {
          "name": "Caspofungin",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "intravenous placebo",
          "type": "DRUG"
        },
        {
          "name": "oral placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2016-07-26",
      "completion_date": "2019-07",
      "has_results": true,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Davis, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02734862"
    },
    {
      "nct_id": "NCT01968902",
      "title": "Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Muscle Spasticity",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "incabotulinumtoxinA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Multiple Sclerosis Center of Northeastern New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2013-11",
      "completion_date": "2016-12-31",
      "has_results": false,
      "last_update_posted_date": "2017-03-22",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 1,
      "location_summary": "Latham, New York",
      "locations": [
        {
          "city": "Latham",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968902"
    },
    {
      "nct_id": "NCT01949844",
      "title": "Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "CAD"
      ],
      "interventions": [
        {
          "name": "regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Optimark®",
          "type": "DRUG"
        },
        {
          "name": "Myocardial perfusion MRI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Daniel S. Berman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2014-05-16",
      "completion_date": "2017-10-23",
      "has_results": true,
      "last_update_posted_date": "2018-08-20",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01949844"
    },
    {
      "nct_id": "NCT03023566",
      "title": "Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Diseases"
      ],
      "interventions": [
        {
          "name": "Dotarem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phoenix Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 250,
      "start_date": "2017-02-09",
      "completion_date": "2017-11-12",
      "has_results": false,
      "last_update_posted_date": "2022-05-20",
      "last_synced_at": "2026-09-08T17:42:38.381Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03023566"
    }
  ]
}